Rupatadine (Fumarate)

Rupatadine (UR-12592) Fumarate is a potent, orally active and long-lasting dual PAF/H1 antagonist, with K_is of 0.55 μM and 0.1 μM, respectively. Rupatadine Fumarate can be used for the research of allergic rhinitis and urticaria^[1][2][3]. In Vitro:Rupatadine Fumarate competitively inhibits histamine-induced guinea pig ileum contraction (pA₂=9.29) without affecting contraction induced by ACh, serotonin or leukotriene D4 (LTD4)^[1].
Rupatadine Fumarate competitively inhibits PAF-induced platelet aggregation in washed rabbit platelets (WRP) (pA₂=6.68) and in human platelet-rich plasma (HPRP) (IC₅₀=0.68 μM), while not affecting ADP- or arachidonic acid-induced platelet aggregation^[1].
Rupatadine (0.1-30 μM) Fumarate inhibits TNF-α secretion in a concentration-dependent manner, with maximum values of 92.5%^[2]. In Vivo:Rupatadine Fumarate blocks histamine- and PAF-induced effects in vivo, such as hypotension in rats (ID₅₀=1.4 and 0.44 mg/kg i.v., respectively) and bronchoconstriction in guinea pigs (ID₅₀=113 and 9.6 μg/kg i.v.)^[1].
Rupatadine Fumarate potently inhibits PAF-induced mortality in mice (ID₅₀=0.31 and 3.0 mg/kg i.v. and p.o., respectively) and endotoxin-induced mortality in mice and rats (ID₅₀=1.6 and 0.66 mg/kg i.v.)^[1].
Rupatadine (6 mg/kg) Fumarate promotes the absorption of the lesions and decreased the density of lungs^[3].